ALVO Alvotech Biopharmaceuticals: Long-Term Debt to Capital Coefficient

Alvotech is developing the biotechnology sector through partnerships with global giants to distribute biosimilars. Historical price action underscores the business's resilience to crises, as demand for chronic disease therapies remains stable and success depends on regulators. The current metric stands at 0.00, however, the company is experiencing a liquidity shortage due to colossal expenditures on clinical trials and product launches.

By focusing biosimilar production within its own laboratories and delegating distribution to partners, Alvotech optimizes capital expenditures, which is reflected in the structure of its long-term liabilities. The current value of 0.00 demonstrates the proportion of loans with a maturity of more than one year to equity, allowing for an assessment of financial stability and leverage risks via the long-term debt-to-equity ratio.